Revenue grew 4.32% and net profit rose 6.10% year-over-year, driven by new drug launches and strong medical device growth. R&D investment remained high at 25.43% of revenue, while cash flow declined. The company expanded its innovative pipeline and completed a key acquisition.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.